Century Therapeutics reported $174.1 million in cash, cash equivalents and investments as of September 30, 2026, supporting operations into 1Q 2029; net loss was $23.5 million for the quarter ended September 30, 2026.
IPSC · Century Therapeutics, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Latest documents
Century Therapeutics targets CNTY-813 IND submission in the fourth quarter of 2026 and initial clinical data in the second half of 2027. Its $174.1 million in cash, cash equivalents and investments will fund operations into the first quarter of 2029.
Century Therapeutics reported CNTY-813 sustained glycemic control for over eleven months, showed consistent production across five clinical-scale batches, and remained functional after 96 hours of cold storage; IND submission is targeted for Q4 2026 and initial clinical data for 2H 2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IPSC
this stock
Century Therapeutics, Inc.
|
$250.60M | +38.7% | +1556.8% | — | 17.6% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.01B | +18.3% | +46.2% | 34.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$97.81B | +22.5% | +20.8% | 20.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.63B | +567.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 12, 2026
- This year
- 23
Century Therapeutics targets CNTY-813 IND submission in the fourth quarter of 2026 and initial clinical data in the second half of 2027. Its $174.1 million in cash, cash equivalents and investments will fund operations into the first quarter of 2029.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IPSC | -20.7% | -14.3% | -43.7% | -6.1% | +38.7% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -16.8% | -8.7% | -40.2% | -2.7% | +31.6% |